The GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTNEW Verify Your Product · test your vial at an approved lab and get the test cost back in store credit →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →Same-day shipping now live from the US West Coast · order by 2:30 PM PT weekdays, 12:00 PM PT Saturday →NEW Verify Your Product · test your vial at an approved lab and get the test cost back in store credit →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →
Disguised Alpha Β· CBL-514 Research

CBL-514’s 2026 Phase IIb MRI Study Explained

Quick answer

The 2026 Phase IIb paper evaluated CBL-514 with clinician ratings, participant ratings and MRI. These are complementary measurements; a rating-scale response should not be presented as though it were an identical imaging result.

Disguised Alpha Β· November 11, 2026 Β· Sources reviewed November 11, 2026

The study’s main question

Lorenc and colleagues reported a randomized, single-blind, placebo-controlled trial involving 108 adults. Its primary endpoint was at least a one-grade improvement on the clinician-reported Abdominal Fat Rating Scale at the 12-week follow-up. Participant ratings and MRI measures were secondary endpoints.[1]

That ordering is essential. The primary endpoint identifies the trial’s principal planned test. Secondary measures can add context, but they should retain their own definitions and analysis conditions.

Why three perspectives are useful

MeasurementQuestion it addresses
Clinician ratingHow did an assessor classify visible abdominal fat?
Participant ratingHow did the participant classify the outcome?
MRIHow did a defined imaging measure change?

Agreement between different measurements can be informative, but the measurements are not substitutes. An observer’s score, a participant’s perception and an imaging volume each have their own sources of variation. A careful review retains all three rather than selecting whichever produces the largest-looking number.

Do not lose the denominator

The abstract reports a clinician-rated response of 23 out of 30 in the CBL-514 group, compared with 7 out of 37 for placebo in the stated analysis. Those denominators differ from overall enrollment.[1] Before comparing percentages, inspect participant flow, analysis exclusions and missing observations.

A useful evidence note records the main endpoint first, then lists secondary findings beneath it. Add an explicit line for missing-data handling. If that line has not been reviewed, the note should say so rather than imply that every randomized participant contributed to every result.

Finally, distinguish evidence about the study formulation from a claim about a supplier’s vial. The publication does not independently establish the identity, manufacturing controls or performance of DA material.

Frequently asked questions

Was MRI the primary endpoint?

The paper identifies the clinician-reported rating-scale response as primary; MRI measurements were secondary.

Why can a trial’s analysis count be smaller than enrollment?

Follow-up availability and analysis rules can change the count. The participant-flow diagram and statistical methods explain the specific reasons.

CBL-514 product and documentation

Review the current format and pack choices, then match the supplied lot to its documentation. No batch-specific identity, purity or content result is asserted in this article.

Sources

  1. Lorenc et al., 2026 Phase IIb study; doi:10.1093/asj/sjag092

Publisher disclosure: Disguised Alpha sells the research material linked here. This supplier-published article provides research education and editorial interpretation; it is not an independent clinical review. Literature findings do not establish the identity or clinical performance of DA material.

Laboratory research only. Not for human or veterinary use. No affiliation with Caliway is claimed.

βœ“
Loading...
25% offGLPs15% off automaticallyUse code GLP or any code for 25% off0days00hrs00min00secShop the sale  →Shop